{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:08:57Z","timestamp":1788592137449,"version":"build-2803163510"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 NS110470"],"award-info":[{"award-number":["K23 NS110470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In a commercial claims database analysis, &amp;lt;0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor\u2013alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.<\/jats:p>","DOI":"10.1093\/cid\/ciae444","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T03:48:26Z","timestamp":1725076106000},"page":"364-366","source":"Crossref","is-referenced-by-count":19,"title":["Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor\u2013Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-9566","authenticated-orcid":false,"given":"Ian","family":"Hennessee","sequence":"first","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"},{"name":"Epidemic Intelligence Service, Centers for Disease Control and Prevention , Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-2493","authenticated-orcid":false,"given":"Kaitlin","family":"Benedict","sequence":"additional","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C","family":"Bahr","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, University of Minnesota , Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R","family":"Lipner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A W","family":"Gold","sequence":"additional","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"2025022409323357400_ciae444-B1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.idc.2020.02.010","article-title":"Fungal infections potentiated by biologics","volume":"34","author":"Davis","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2025022409323357400_ciae444-B2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor \u03b1 blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2025022409323357400_ciae444-B3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41577-022-00826-w","article-title":"Immune responses to human fungal pathogens and therapeutic prospects","volume":"23","author":"Lionakis","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025022409323357400_ciae444-B4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ299","article-title":"Histoplasmosis complicating tumor necrosis factor\u2013\u03b1 blocker therapy: a retrospective analysis of 98 cases","volume":"61","author":"Vergidis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025022409323357400_ciae444-B5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2025022409323357400_ciae444-B6","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"2025022409323357400_ciae444-B7","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"2025022409323357400_ciae444-B8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2024.03.046","article-title":"Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating TNF-alpha inhibitors for dermatologic conditions","volume":"91","author":"Hennessee","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025022409323357400_ciae444-B9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025022409323357400_ciae444-B10","doi-asserted-by":"crossref","first-page":"e36450","DOI":"10.1097\/MD.0000000000036450","article-title":"Incidence of histoplasmosis in patients receiving TNF-alpha inhibitors: a systematic review and meta-analysis","volume":"102","author":"Cipolat","year":"2023","journal-title":"Medicine"},{"key":"2025022409323357400_ciae444-B11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2165\/00003495-200969110-00002","article-title":"Endemic fungal infections in patients receiving tumour necrosis factor-\u03b1 inhibitor therapy","volume":"69","author":"Smith","year":"2009","journal-title":"Drugs"},{"key":"2025022409323357400_ciae444-B12","doi-asserted-by":"crossref","first-page":"otad010","DOI":"10.1093\/crocol\/otad010","article-title":"Corticosteroids increase the risk of invasive fungal infections more than tumor necrosis factor-alpha inhibitors in patients with inflammatory bowel disease","volume":"5","author":"Gregory","year":"2023","journal-title":"Crohns Colitis 360"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae444\/59394162\/ciae444.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/2\/364\/59394162\/ciae444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/2\/364\/59394162\/ciae444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:34:39Z","timestamp":1740371679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/2\/364\/7748004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2025,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae444","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,9,3]]}}}